ライフサイエンスコーパス: antithymocyte

1 Patients receiving antithymocyte antibody had a lower recurrence rate than

2 ing responses to horse and rabbit polyclonal antithymocyte antibody preparations.

3 Antithymocyte/antilymphocyte globulins are polyclonal an

4 ic CMVIG and induction with high-dose rabbit antithymocyte globulin (>10 mg/kg) were associated with

5 e randomly assigned to receive either rabbit antithymocyte globulin (1.5 mg per kilogram of body weig

6 ence was seen between alemtuzumab and rabbit antithymocyte globulin (18% vs. 15%, P=0.63).

7 emental thymic irradiation (7 Gy on day -1), antithymocyte globulin (50 mg/kg on days -2, -1, and 0),

8 along with cyclophosphamide (200 mg/kg) and antithymocyte globulin (6 mg/kg) (n = 55) or DMT of high

9 nditioning regimen used was CYC (200 mg/kg), antithymocyte globulin (90 mg/kg), and methylprednisolon

10 gimen included cyclophosphamide (200 mg/kg), antithymocyte globulin (90 mg/kg), and, for 1 patient, t

11 ng, cyclophosphamide (120 mg/kg), and equine antithymocyte globulin (90 mg/kg).

12 with cyclophosphamide (200 mg/kg) and equine antithymocyte globulin (90 mg/kg).

13 orin (CSA) alone or the combination of horse antithymocyte globulin ([ATG] Lymphoglobuline; Merieux,

14 one dose of 30 mg, in 70 patients) or rabbit antithymocyte globulin (a total of 6 mg per kilogram of

15 groups based on induction immunosuppression: antithymocyte globulin (ATG) (n=85) or basiliximab (n=29

16 Antithymocyte globulin (ATG) + cyclosporine is effective

17 However, our randomized trial comparing antithymocyte globulin (ATG) and Cy was terminated early

18 otal body irradiation, cyclophosphamide, and antithymocyte globulin (ATG) and was followed by transpl

19 Eighty-two patients received rabbit antithymocyte globulin (ATG) as part of the conditioning

20 ate similar to that with regimens containing antithymocyte globulin (ATG) but neither relapse nor clo

21 Lymphocyte depletion with antithymocyte globulin (ATG) can be complicated by syste

22 Optimizing antithymocyte globulin (ATG) dosage is critical, particu

23 C using total lymphoid irradiation (TLI) and antithymocyte globulin (ATG) followed by the infusion of

24 ndomized clinical trial comparing ABX-CBL to antithymocyte globulin (ATG) for treatment of steroid-re

25 We previously showed that antithymocyte globulin (ATG) given with total body irrad

26 Antithymocyte globulin (ATG) has been used in allogeneic

27 Antithymocyte globulin (ATG) has recently been populariz

28 Daclizumab and antithymocyte globulin (ATG) have been shown to reduce a

29 The impact of antithymocyte globulin (ATG) in the setting of a myeloab

30 ences were not seen among patients receiving antithymocyte globulin (ATG) induction (aRR for AR, 1.16

31 rawal after liver transplantation (LT) using antithymocyte globulin (ATG) induction and rapamycin.

32 Total lymphoid irradiation (TLI) with antithymocyte globulin (ATG) is a unique regimen that pr

33 Antithymocyte globulin (ATG) is used as induction therap

34 Polyclonal antithymocyte globulin (ATG) is widely used as an anti-T

35 Moreover, combining PTCY with antithymocyte globulin (ATG) may help to reduce GVHD inc

36 udies and pilot clinical trials suggest that antithymocyte globulin (ATG) might be effective for redu

37 ersial, particularly regarding concerns that antithymocyte globulin (ATG) might increase HCV-related

38 We evaluated the effect of antithymocyte globulin (ATG) on anti-human leukocyte ant

39 We studied the impact of early, late, and no antithymocyte globulin (ATG) on immune reconstitution an

40 Immunosuppression with antithymocyte globulin (ATG) or cyclosporine (CSA) can b

41 iated with a clinically relevant response to antithymocyte globulin (ATG) or cyclosporine immunosuppr

42 tion or in vivo T-cell depletion with either antithymocyte globulin (ATG) or monoclonal anti-T-cell a

43 Immunosuppressive therapy with antithymocyte globulin (ATG) plus cyclosporine is an eff

44 Low-dose antithymocyte globulin (ATG) plus pegylated granulocyte

45 Depletional induction using antithymocyte globulin (ATG) reduces rates of acute reje

46 The addition of antithymocyte globulin (ATG) to a regimen of high-dose c

47 ddition of low, nondepleting doses of rabbit antithymocyte globulin (ATG) to human peripheral blood m

48 ) with T-cell depletion of the donor marrow, antithymocyte globulin (ATG) use, and unrelated or HLA-m

49 ith an NMA preparative regimen that included antithymocyte globulin (ATG) versus those that did not (

50 ed with total lymphoid irradiation (TLI) and antithymocyte globulin (ATG) were given kidney transplan

51 data support replacing BuCy2 with or without antithymocyte globulin (ATG) with Bu-Flu with or without

52 e fraction total body irradiation (TBI), and antithymocyte globulin (ATG) with or without fludarabine

53 ed the ability of the immune-depleting agent antithymocyte globulin (ATG), as well as the mobilizatio

54 erapy and 93 (>25, 386; n=3) days with added antithymocyte globulin (ATG), but did not yield toleranc

55 oning regimen--whole body irradiation (WBI), antithymocyte globulin (ATG), extracorporeal immunoadsor

56 ive nonmyeloablative protocols using TLI and antithymocyte globulin (ATG), followed by allogeneic hem

57 se using various combinations of four drugs: antithymocyte globulin (ATG), granulocyte-colony stimula

58 -lymphoid irradiation (TLI), with or without antithymocyte globulin (ATG), have been shown to develop

59 Thymoglobulin, a rabbit polyclonal antithymocyte globulin (ATG), is a widely used induction

60 s, induction with antilymphocyte globulin or antithymocyte globulin (ATG), or use of ATG or OKT3 for

61 nts receiving total body irradiation without antithymocyte globulin (ATG), whereas the relapse risk w

62 tosus, conditioned with a regimen containing antithymocyte globulin (ATG), who developed factor VIII

63 al greater than 80 days using a steroid-free antithymocyte globulin (ATG)-based induction regimen (AT

64 res of 12 patients with MDS before and after antithymocyte globulin (ATG)-based treatment by T-cell r

65 he cardiovascular consequences of polyclonal antithymocyte globulin (ATG)-induced immune modification

66 mes with steroids alone versus steroids plus antithymocyte globulin (ATG).

67 some of whom were undergoing treatment with antithymocyte globulin (ATG).

68 Patients received immunosuppression with antithymocyte globulin (ATG)/cyclosporine (CsA) or cyclo

69 experience using dual-induction therapy with antithymocyte globulin (ATG)/daclizumab (Dac) (each with

70 ody irradiation (TBI) required when added to antithymocyte globulin (ATG, 30 mg/kg x 3) plus cyclopho

71 clophosphamide (200 mg/kg) and either equine antithymocyte globulin (ATG, 90 mg/kg) or rabbit ATG (6

72 de (200 mg/kg), methylprednisolone (4 g) and antithymocyte globulin (ATG; 90 mg/kg) or myeloablative

73 s according to whether conditioning included antithymocyte globulin (ATG; n = 191) or alemtuzumab (n

74 splantation either with (n = 241) or without antithymocyte globulin (ATG; n = 491) following reduced-

75 003 to 2004 received no induction (n=4,364), antithymocyte globulin (ATG; n=4,930), interleukin-2 rec

76 t and 19 lung transplant recipients received antithymocyte globulin (ATGAM or thymoglobulin) as induc

77 Fludarabine, busulfan, and antithymocyte globulin (Fd/Bu/ATG) was associated with t

78 m immunosuppressive therapy (IST) with horse antithymocyte globulin (h-ATG) and cyclosporine (CsA) ca

79 arly phase of allogeneic HCT were receipt of antithymocyte globulin (HR, 22.77 [95% CI, 4.85-101.34])

80 nce interval [CI]=1.16-1.81), induction with antithymocyte globulin (HR: 1.43, 95% CI=1.075-1.94), an

81 Mouse antithymocyte globulin (mATG) prevents, as well as rever

82 usulfan (Bu)/alemtuzumab (n = 8), and Flu/Bu/antithymocyte globulin (n = 1).

83 py was with MMF, tacrolimus, prednisone, and antithymocyte globulin (n=109) or OKT3 (n=2).

84 eukin (IL)-2-receptor antagonists (n=217) or antithymocyte globulin (n=64).

85 (P = 0.046) as well as those having received antithymocyte globulin (P < 0.001) were more likely to d

86 LA-DR mismatches (P = 0.008), induction with antithymocyte globulin (P = 0.0001), and pretransplant p

87 atologic improvement after administration of antithymocyte globulin (P = 0.0015).

88 mber 2008 who received induction with rabbit-antithymocyte globulin (r-ATG), alemtuzumab, or an inter

89 ategories: no-induction, alemtuzumab, rabbit antithymocyte globulin (r-ATG), and interleukin-2 recept

90 randomized for 3 different regimens: rabbit antithymocyte globulin (r-ATG)/EVR (N = 85); basiliximab

91 we generated 1:1 pairs of alemtuzumab-rabbit antithymocyte globulin (rATG) (5330 pairs) and basilixim

92 ts were treated with T cell-depleting rabbit antithymocyte globulin (rATG) (6 mg/kg, n = 17) or nonde

93 emtuzumab induction was compared with rabbit antithymocyte globulin (rATG) (Thymoglobulin [Genzyme] o

94 ategies have not been established for rabbit antithymocyte globulin (rATG) after heart transplantatio

95 Rabbit antithymocyte globulin (rATG) and horse ATG (hATG) are w

96 reatment using induction therapy with rabbit antithymocyte globulin (RATG) and intravenous immunoglob

97 Alemtuzumab and rabbit antithymocyte globulin (rATG) are commonly used for indu

98 Despite the prevalent use of rabbit antithymocyte globulin (rATG) as an induction agent in k

99 safety and efficacy of induction with rabbit antithymocyte globulin (RATG) compared with interleukin-

100 ients who received either steroids or rabbit antithymocyte globulin (RATG) for orthotopic liver trans

101 recipients who received rituximab and rabbit antithymocyte globulin (rATG) in combination as inductio

102 free immunosuppression protocol using rabbit antithymocyte globulin (RATG) induction in orthotopic li

103 Rabbit antithymocyte globulin (rATG) induction is associated wi

104 Optimal dosing of rabbit antithymocyte globulin (rATG) induction therapy in kidne

105 ge, we developed a protocol to extend rabbit antithymocyte globulin (rATG) induction therapy into the

106 5 mg versus MMF in patients receiving rabbit antithymocyte globulin (rATG) induction, mainly due to i

107 ers comparing a control group of with rabbit antithymocyte globulin (rATG) induction, rapid steroid t

108 Induction rabbit antithymocyte globulin (rATG) is largely used in renal a

109 who were randomized to receive either rabbit antithymocyte globulin (RATG) or steroids as induction t

110 ere evaluated before and after adding rabbit antithymocyte globulin (rATG) to mixed lymphocyte co-cul

111 Rabbit-derived antithymocyte globulin (rATG) treatment reduces the inci

112 single-dose (SD) versus divided-dose rabbit antithymocyte globulin (rATG), and a maintenance arm (pa

113 Thymoglobulin, rabbit antithymocyte globulin (RATG), has been shown to be effe

114 man leukocyte antigen (HLA) mismatch, rabbit antithymocyte globulin (RATG), interleukin-2 receptor an

115 proliferation by Ki-67(+) T cells in rabbit antithymocyte globulin (rATG)-treated patients the first

116 bined therapy with PPH and polyclonal rabbit antithymocyte globulin (rATG).

117 exposed (4.23%) versus not exposed to rabbit antithymocyte globulin (rATG; 0.53%; P=0.019) or SPK (9.

118 iximab (1998), daclizumab (1998), and rabbit antithymocyte globulin (rATG; 1999) replaced antilymphoc

119 ognostic influence of induction type: rabbit antithymocyte globulin (rATG; 2 mg/kg x 5)/rituximab (15

120 ed to assess clinical experience with rabbit antithymocyte globulin (rATG; Thymoglobulin) in living d

121 Rabbit antithymocyte globulin (rATG; thymoglobulin, Genzyme) in

122 tion of donor marrow (RR = 12.7), and use of antithymocyte globulin (RR = 6.4) or anti-CD3 monoclonal

123 imary kidney transplant recipients comparing antithymocyte globulin (Thymoglobulin) (group A, N=43) v

124 eatment with approximately 5 mg/kg of rabbit antithymocyte globulin (Thymoglobulin) in the hours befo

125 Recipients were treated with 7 doses of antithymocyte globulin (Thymoglobulin, day 1 to 9), siro

126 omized, international study comparing rabbit antithymocyte globulin (TMG) and basiliximab (BAS) induc

127 mphoid irradiation of 80 cGy for 10 days and antithymocyte globulin 1.5 mg/kg/d for 5 days.

128 otal body irradiation, cyclophosphamide, and antithymocyte globulin [ATG] with cyclosporine A and met

129 Polyclonal antihuman thymocyte rabbit IgGs (antithymocyte globulin [ATG]) are popular immunosuppress

130 (ATS) (the murine preclinical equivalent of antithymocyte globulin [ATG]) facilitates immune toleran

131 ual care (the control group was treated with antithymocyte globulin [ATG]).

132 omes after in vivo T-cell depletion (n = 584 antithymocyte globulin [ATG]; n = 213 alemtuzumab) were

133 A dose of 40 mg/kg per day of antithymocyte globulin administered for 4 days, 10 to 12

134 f haploidentical marrow grafts, who received antithymocyte globulin after bone marrow transplantation

135 ng regimen of total lymphoid irradiation and antithymocyte globulin allowed engraftment of the donor'

136 teroid withdrawal protocol; 9 of 11 received antithymocyte globulin and 2 received basiliximab induct

137 eived a conditioning regimen including horse antithymocyte globulin and aCD40/Bela.

138 included induction with a steroid taper and antithymocyte globulin and anti-CD20 monoclonal antibody

139 national study, we compared short courses of antithymocyte globulin and basiliximab in patients at hi

140 ransplantation, immunosuppression (generally antithymocyte globulin and ciclosporin), and high-dose c

141 st-line immunosuppressive therapy (IST) with antithymocyte globulin and cyclosporin and is manifested

142 immunosuppressive therapy with drugs such as antithymocyte globulin and cyclosporine have clonal expa

143 nts with severe aplastic anemia treated with antithymocyte globulin and cyclosporine have durable rec

144 Antithymocyte globulin and cyclosporine restore hematopo

145 standard immunosuppressive regimens, such as antithymocyte globulin and cyclosporine.

146 let Transplantation 07 (CIT07) protocol uses antithymocyte globulin and etanercept induction, islet c

147 re less than 150 and 250, respectively, with antithymocyte globulin and intravenous immunoglobulin in

148 We conclude that induction with antithymocyte globulin and maintenance immunosuppression

149 sisted of high-dose cyclophosphamide, equine antithymocyte globulin and pretransplant thymic irradiat

150 The use of antithymocyte globulin and prolonged exposure to gancicl

151 , contributes to the therapeutic efficacy of antithymocyte globulin and suggest that time-dependent w

152 rapy agents, growth factor combinations, and antithymocyte globulin appear promising and are reviewed

153 ition of melphalan, and the incorporation of antithymocyte globulin appear to have contributed to bet

154 eroid maintenance therapy and induction with antithymocyte globulin are independent risk factors for

155 CMV disease, attributable to high levels of antithymocyte globulin at the time of T cell infusion.

156 reatment study, 34% of patients treated with antithymocyte globulin became transfusion independent.

157 ymic irradiation before transplantation, and antithymocyte globulin before and after transplantation.

158 cytarabine, and melphalan as well as rabbit antithymocyte globulin before autologous HCT.

159 ome received busulfan, cyclophosphamide, and antithymocyte globulin before receiving cord-blood trans

160 armustine, etoposide, cytarabine, melphalan)+antithymocyte globulin chemotherapeutic regimen.

161 t recipients who received induction doses of antithymocyte globulin combined with maintenance immunot

162 alemtuzumab-based conditioning with standard antithymocyte globulin conditioning regimens, lower rate

163 A regimen of total lymphoid irradiation plus antithymocyte globulin decreases the incidence of acute

164 Treatment with antithymocyte globulin did not seem to be detrimental be

165 Ganciclovir-resistant patients received more antithymocyte globulin during induction (70+/-44 vs. 45+

166 h about 5 mg/kg of a broadly reacting rabbit antithymocyte globulin during several hours.

167 Rabbit antithymocyte globulin facilitates apoptosis of alloreac

168 herefore tested T-cell depletion with rabbit antithymocyte globulin followed by sirolimus monotherapy

169 tations from unrelated donors and were given antithymocyte globulin for GVHD prophylaxis.

170 The total amount of antithymocyte globulin given to each CD3 monitored patie

171 drugs such as tacrolimus, mycophenolate, or antithymocyte globulin go on shortage.

172 The antithymocyte globulin group and the basiliximab group h

173 The antithymocyte globulin group, as compared with the basil

174 r between the two groups, patients receiving antithymocyte globulin had a greater incidence of infect

175 g high-risk patients, alemtuzumab and rabbit antithymocyte globulin had similar efficacy.

176 ely) were low and associated with the use of antithymocyte globulin in 91% of patients.

177 ired steroid therapy and one required rabbit antithymocyte globulin in addition to MMF and steroids.

178 with interleukin-2 receptor antagonists, and antithymocyte globulin in high-risk recipients.

179 onmyeloablative conditioning, and absence of antithymocyte globulin in the conditioning regimen.

180 results demonstrate that in a murine system, antithymocyte globulin induces cells with suppressive ac

181 ere enrolled in a prospective study in which antithymocyte globulin induction and 6 days of corticost

182 uired in SPK transplant recipients receiving antithymocyte globulin induction and maintenance immuno-

183 Immunosuppression consisted of antithymocyte globulin induction and maintenance with si

184 ients of intraportal islet cell grafts under antithymocyte globulin induction and mycophenolate mofet

185 ntenance prednisone in the setting of rabbit antithymocyte globulin induction and tacrolimus and siro

186 Almost all patients received antithymocyte globulin induction and were maintained on

187 Immunosuppression consisted of antithymocyte globulin induction followed by mycophenola

188 ined PAK (n=47) transplants receiving rabbit antithymocyte globulin induction from June 1998 to June

189 CI], 1.2 to 6.6; P=0.02) and those receiving antithymocyte globulin induction therapy (hazard ratio,

190 nor, thin ureters at kidney transplantation, antithymocyte globulin induction therapy, blood transfus

191 An early steroid withdrawal regimen with antithymocyte globulin induction was associated with exc

192 od II (post-August 2001) with alemtuzumab or antithymocyte globulin induction with steroid avoidance.

193 k renal transplant patients usually involves antithymocyte globulin induction with triple drug mainte

194 corticosteroid withdrawal regimen of rabbit antithymocyte globulin induction, tacrolimus, and mycoph

195 pression consisted of quadruple therapy with antithymocyte globulin induction, tacrolimus, MMF, and p

196 corticosteroid withdrawal regimen of rabbit antithymocyte globulin induction, tacrolimus, mycophenol

197 yclosporine and corticosteroids after rabbit antithymocyte globulin induction.

198 All patients received antithymocyte globulin induction.

199 Antithymocyte globulin is frequently used as a component

200 Induction therapy with rabbit antithymocyte globulin may achieve a short-term decrease

201 CMVIG and appropriate induction with rabbit antithymocyte globulin may be important to reduce CMV in

202 nt pretreatment with a single dose of rabbit antithymocyte globulin or alemtuzumab and posttransplant

203 Describe the safety and efficacy of antithymocyte globulin or alemtuzumab preconditioning, s

204 e fludarabine based and T cell depleted with antithymocyte globulin or alemtuzumab.

205 fetil were required as well as either rabbit antithymocyte globulin or interleukin-2 receptor antibod

206 fractory cases, alternative regimens such as antithymocyte globulin or monoclonal antibody therapy ha

207 unosuppressive regimens that included rabbit antithymocyte globulin or tacrolimus/mycophenolate combi

208 hosphamide, and 6.5 mg/kg intravenous rabbit antithymocyte globulin or to receive 1.0 g/m(2) intraven

209 should be considered for a second course of antithymocyte globulin plus cyclosporin, although respon

210 enrolled in immunosuppression protocols with antithymocyte globulin plus cyclosporine for correlation

211 onsisting of busulfan, cyclophosphamide, and antithymocyte globulin plus or minus etoposide.

212 lant, and patients did not routinely receive antithymocyte globulin posttransplant.

213 efine the efficacy of a busulfan/fludarabine/antithymocyte globulin RIC regimen in pediatric patients

214 Patients who were randomized to antithymocyte globulin therapy (ATGAM, ATG) received 15

215 ipheral CD3 lymphocytes to rationally adjust antithymocyte globulin therapy in this patient populatio

216 CD3 monitoring of antithymocyte globulin therapy in thoracic organ recipie

217 rotocol applied including plasmapheresis and antithymocyte globulin treatment as well as cyclophospha

218 Although in vitro antithymocyte globulin treatment resulted in a dramatic

219 the patients) was defined as requirement for antithymocyte globulin treatment within 2 weeks after co

220 Age, history of antithymocyte globulin use, smoking, and history of canc

221 with Aspergillus colonization, use of rabbit antithymocyte globulin was associated with 4-fold risk o

222 -2-receptor induction with daclizumab versus antithymocyte globulin was independently associated with

223 ortional hazard model, treatment with rabbit antithymocyte globulin was significantly associated with

224 Historically, antithymocyte globulin was used when patients did not re

225 With CD3 monitoring, the doses of antithymocyte globulin were reduced from 10-15 mg/kg to

226 prophylaxis, all but 2 received serotherapy (antithymocyte globulin) before HSCT and a short course o

227 er ex vivo nor in vivo T-cell depletion (eg, antithymocyte globulin) convincingly improved outcomes.

228 vidualized conditioning and serotherapy (eg, antithymocyte globulin), nutritional status, exercise, h

229 nduction therapy (antilymphocyte globulin or antithymocyte globulin), whereas LRD recipients did not.

230 nal induction therapy (basiliximab or rabbit antithymocyte globulin).

231 and consecutive LT patients receiving rabbit antithymocyte globulin+/-rituximab induction were studie

232 With the use of rabbit antithymocyte globulin+/-rituximab induction, overall lo

233 Antithymocyte globulin, 40 mg/kg of body weight, given d

234 ession, all patients received induction with antithymocyte globulin, a brief taper of intravenous sol

235 tion, the ATG group (13 recipients) received antithymocyte globulin, although the LOCD2b group (10 re

236 n posttransplant total lymphoid irradiation, antithymocyte globulin, and a single infusion of ACI per

237 I and thymic irradiation, pretransplantation antithymocyte globulin, and immunoadsorption of anti-Gal

238 total body irradiation, thymic irradiation, antithymocyte globulin, and peritransplant CD154 blockad

239 multivariable analysis, CMV-CMI, sex, race, antithymocyte globulin, and steroid use were independent

240 nt after conditioning with cyclophosphamide, antithymocyte globulin, and thymic irradiation.

241 tion therapy consisting of a 5-day course of antithymocyte globulin, as compared with basiliximab, re

242 splant recipients who were prescribed rabbit antithymocyte globulin, calcineurin inhibitor, mycopheno

243 (700 cGy) irradiation, T cell depletion with antithymocyte globulin, complement depletion with cobra

244 total body irradiation, thymic irradiation, antithymocyte globulin, donor bone marrow transplantatio

245 The regimen consisted of antithymocyte globulin, fludarabine, cyclophosphamide, a

246 otal lymphoid irradiation (80 cGy each) plus antithymocyte globulin, followed by an infusion of HLA-m

247 re acute rejection resistant to steroids and antithymocyte globulin, histologic evidence of plasma ce

248 1997 using a similar induction protocol with antithymocyte globulin, mycophenolate mofetil, prednison

249 umab (versus no induction, anti-CD25, rabbit antithymocyte globulin, or rabbit antithymocyte globulin

250 le body and thymic irradiation, splenectomy, antithymocyte globulin, pharmacologic immunosuppression

251 out granulocyte colony-stimulating factor or antithymocyte globulin, respectively.

252 Subjects received rabbit antithymocyte globulin, tacrolimus, mycophenolate mofeti

253 itioning with total lymphoid irradiation and antithymocyte globulin, the fraction of donor CD4+ T cel

254 h anti-T-lymphocyte globulin (ATLG; formerly antithymocyte globulin-Fresenius) reduces chronic graft-

255 To examine whether antithymocyte globulin-induced regulatory cells might be

256 ession was Tac-Pred based in nine and rabbit antithymocyte globulin-Tac based in six cases.

257 as carried out under Tac-Pred in six, rabbit antithymocyte globulin-Tac in eight, and alemtuzumab mon

258 id irradiation, cyclophosphamide, and rabbit-antithymocyte globulin.

259 were mostly cyclophosphamide with or without antithymocyte globulin.

260 ther 20 mg alemtuzumab or 6 mg per kg rabbit antithymocyte globulin.

261 men included busulfan, cyclophosphamide, and antithymocyte globulin.

262 nsity conditioning with cyclophosphamide and antithymocyte globulin.

263 ablative dosages of busulfan, melphalan, and antithymocyte globulin.

264 0 mg/kg cyclophosphamide and 90 mg/kg equine antithymocyte globulin.

265 mg/kg cyclophosphamide, and 90 mg/kg equine antithymocyte globulin.

266 isting of cyclophosphamide, fludarabine, and antithymocyte globulin.

267 1 g methylprednisolone, and 90 mg/kg equine antithymocyte globulin.

268 myelodysplasia, or renal allografts received antithymocyte globulin.

269 renal allograft recipients who had received antithymocyte globulin.

270 grade 2A rejection successfully treated with antithymocyte globulin.

271 duced-intensity conditioning, and the use of antithymocyte globulin.

272 leukocyte antigen mismatch, age, and use of antithymocyte globulin.

273 mib, methylprednisone, rituximab, and rabbit antithymocyte globulin.

274 d elimination at 1 week, and combined rabbit antithymocyte globulin/daclizumab induction, previously

275 25, rabbit antithymocyte globulin, or rabbit antithymocyte globulin/rituximab) induction (P = 0.004),

276 Polyclonal antithymocyte globulins (ATGs) are used clinically to pr

277 Antithymocyte globulins (ATGs) are used to prevent and t

278 Rabbit-generated antithymocyte globulins (ATGs), which target human T cel

279 Polyclonal antithymocyte globulins (AThG) are a subset of antilymph

280 -) and 104 seropositive recipients receiving antithymocyte globulins (R+/ATG).

281 r patients who have undergone thymoglobulin (antithymocyte globulins [ATG]) or basiliximab (BSX) ther

282 Immunosuppression included antithymocyte globulins and bone-marrow infusion then st

283 Immunosuppression with antithymocyte globulins and cyclosporine is effective at

284 89 kidney transplant recipients treated with antithymocyte globulins and prednisone.

285 With antithymocyte globulins and steroids, clinically suspect

286 Thus, in both murine and human systems, antithymocyte globulins not only deplete T cells, but al

287 time, delayed graft function, induction with antithymocyte globulins, acute rejection before month 3

288 Selected patients respond to antithymocyte globulins, and thrombopoietin receptor ago

289 imus, mycophenolate mofetil, prednisone, and antithymocyte globulins.

290 uccessful induction therapy using two rabbit antithymocyte globulins.

291 ate mofetil, prednisone, and, for induction, antithymocyte globulins.

292 A rabbit antithymocyte polyclonal antibody or basiliximab, an int

293 intraoperative administration of polyclonal antithymocyte preparations may reduce the incidence of D

294 total lymphoid irradiation (TLI) and rabbit antithymocyte serum (ATS) (the murine preclinical equiva

295 Peritransplant treatment with antithymocyte serum (ATS) and posttransplantation admini

296 tion of donor spleen or donor bone marrow in antithymocyte serum (ATS) treated recipients.

297 one marrow to augment skin graft survival in antithymocyte serum (ATS)-treated recipients is dependen

298 ng regimen of total lymphoid irradiation and antithymocyte serum (TLI/ATS) in mice that has been rece

299 tation of donor Treg proliferation after TLI/antithymocyte serum is IL-4 dependent.

300 tioning with total lymphoid irradiation plus antithymocyte serum protects mice against acute graft-ve